Targets › SIRT1
2 programs from 2 companies in 2 trials: 2 Phase 2; Respiratory, Neurology; next expected readout Jan 2027.
NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metabolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to…. (UniProt, Q96EB6)
Open in Phaseline: the race on SIRT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Nicotinamide riboside NAD+ precursor; may enhance mitochondrial function and cellular stress responses | SIRT1 | Phase 2 | Idiopathic Pulmonary Fibrosis | Jan 2027 |
| Georgetown University | Trans-Resveratrol (JOTROL) SIRT1 activator; stimulates mitochondrial biogenesis and mitochondrial dynamics via autoph | SIRT1 | Phase 2 | Parkinson's Disease | Jun 2028 |
Idiopathic Pulmonary Fibrosis (1) Parkinson's Disease (1)
small molecule (2)
Cedars-Sinai Medical Center (1) Georgetown University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.